Ezetimibe inhibits triple-negative breast cancer proliferation and promotes cell cycle arrest by targeting the PDGFR/AKT pathway

Cholesterol levels were strongly associated with tumor progression and metastasis. Targeted cholesterol metabolism has broad prospects in tumor treatment. Ezetimibe, the only FDA-approved inhibitor of cholesterol absorption, has been reported to be able to inhibit angiogenesis in liver cancer. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Qinyu, Kong, Lingkai, Shi, Weiwei, Ma, Ding, Liu, Kua, Yang, Shuwei, Xin, Qilei, Jiang, Chunping, Wu, Junhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651468/
https://www.ncbi.nlm.nih.gov/pubmed/38027998
http://dx.doi.org/10.1016/j.heliyon.2023.e21343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651468/
https://www.ncbi.nlm.nih.gov/pubmed/38027998
http://dx.doi.org/10.1016/j.heliyon.2023.e21343

Ejemplares similares